by John Conrad | Aug 4, 2025 | Policy News
Illinois companies stand to lose $90 million in annual funding if federal programs expire September 30th Illinois life sciences companies and associations have until August 15th to sign onto a group letter urging the state’s Congressional Delegation to...
by John Conrad | May 12, 2025 | Policy News
“The President’s Most Favored Nation proposal represents a catastrophic misstep for American biosciences innovation and patient access to life-saving treatments,” said John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization. “This...
by John Conrad | Apr 16, 2025 | Policy News
iBIO recognizes the significance of the Trump Administration’s recent Executive Order addressing drug pricing in the United States. We particularly welcome the Administration’s acknowledgment of the “pill penalty” issue and examination of PBM...
by John Conrad | Feb 20, 2025 | Policy News
“Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a...
by John Conrad | Nov 5, 2024 | Policy News
Disclaimer: iBIO is a nonpartisan organization and does not endorse any candidate for public office. This article is provided for informational purposes only to help our members understand potential policy implications of election outcomes. As voters head to the polls...
by John Conrad | Oct 3, 2024 | Policy News
The Centers for Medicare & Medicaid Services (CMS) has announced significant changes to its drug price negotiation process for the Medicare program. These updates come in response to feedback from patients and pharmaceutical companies following the first round of...
